Clinical Trial On Treating Non-alcoholic Fatty Liver Disease Of Liver Stagnation And Spleen Deficiency With Tiaoganlipi Formula

Objective:To observe the clinical effect and safety of treating non-alcoholic fatty liverdisease of liver stagnation and spleen deficiency with Tiaoganlipi formula.Methods:99patients with non-alcoholic fatty liver disease of liver stagnation and spleendeficiency were divided into treatment group with66cases and control group with33cases randomly. The treatment group was treated by Tiaoganlipi formula for12weeks, while control group was treated by placebo, and both of the groups receivedinterventions from lifestyle changes which include moderate aerobic, moderatecaloric restriction and change of diet. Clinical symptoms, liver function, blood lipid,CT index, adverse reactions were observed and compared before and after the twodifferent treatments.Results:There is a significant difference between treatment group and control group inthe CT features of liver after treatment, and the treatment group improved theimaging features of NAFLD while the control group didn’t. Significant disfferenceswere found in lowering the liver function by the treatment group, and the same caseswere not found in the control group. Both of the two groups have significantlyimproved the clinical symptoms and quality of life, lowered blood lipid after thetreatment, and differences showed up between the two groups in the changes of thescores. Side effects were not found during the research in both of the two groups.Conclusion:It is safe and effective to treat non-alcoholic fatty liver disease of liverstagnation and spleen deficiency with Tiaoganlipi formula coordinated with changesof life style.